Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)

Trial Profile

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Heart failure; Iron deficiency anaemia; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms IRONMAN
  • Most Recent Events

    • 13 Dec 2016 Planned End Date changed from 1 Aug 2020 to 1 Feb 2021.
    • 13 Dec 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2021.
    • 19 Aug 2016 Accordign to a Pharmacosmos media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top